natgillin/translations-raw huggingface dataset:
Three to six hours after the injection, the doctor takes a scan of the limbs to locate the areas in the bones affected by osteomyelitis.
3–6 tundi pärast süstimist skaneerib arst jäsemed, et teha kindlaks luupiirkonnad, kus esineb osteomüeliit.
Three to six months are required after the initiation of therapy for equilibration to occur.
Selle saavutamiseks kulub ravi algusest kolm kuni kuus kuud.
Three to six months are required after the initiation of therapy for equilibration to occur.
Stabiilse taseme saavutamiseks kulub kolm kuni kuus kuud ravi alustamisest.
Three tubes of breath are to be taken, which are used to measure the presence of excess levels of 13C, which will be present if the patient is H. pylori positive.
Väljahingatav õhk tuleb võtta kolme katsutisse, mida kasutatakse liigse 13C taseme mõõtmiseks (liigne 13C esineb siis, kui patsient on H. pylori-positiivne).
Three years data showed a decrease in the incidence of gout flares with less than 4% of patients requiring treatment for a flare (i.e. more than 96% of patients did not require treatment for a flare) at Month 16-24 and at Month 30-36.
Kolme aasta andmed näitasid, podagrahoogude sageduse vähenemist, kuna vähem kui 4% patsientidest vajas 16.–24. kuul ja 30. ja 36 kuul podagrahoo ravi (s.t rohkem kui 96% patsientidest podagrahoo ravi ei vajanud).
Three, 6 month, double-blind, placebo-controlled clinical studies were conducted in ESRD patients with uncontrolled secondary HPT receiving dialysis (n=1136).
Dialüüsravi saavate ESRD patsientidega (n=1136), kellel oli ravimata sekundaarne HPT, teostati topeltpime- meetodil kolm 6-kuulist platseebokontrolliga uuringut.
Three, 6-month, double-blind, placebo-controlled clinical studies were conducted in ESRD patients with uncontrolled secondary HPT receiving dialysis (n=1136).
Dialüüsravi saavate ESRD patsientidega (n=1136), kellel oli ravimata sekundaarne HPT, teostati topeltpime-meetodil kolm 6-kuulist platseebokontrolliga uuringut.
Three-dose primary series
Kolme annusega esmavaktsineerimine
Three-dose primary series
Kolmeannuseline esmane vaktsineerimine
Three-sigma threshold value
Kolme sigma künnisväärtus
Three-weekly schedule
Kolmenädalaste intervallidega raviskeem
Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data.
Neeru– ja südametransplantaadiga patsientidel ei esinenud kolmeaastase jälgimisperioodi jooksul võrreldes üheaastase jälgimisperioodiga mingeid muutusi pahaloomuliste kasvajate esinemissageduses.
throat and mouth yeast infection vaginal infection
neelu ja suu seeninfektsioon tupepõletik
throat infection
kurgupõletik
throat infections  dry eyes
neeluinfektsioonid
throat inflammation
kurgupõletik
throat inflammation that causes a hoarse voice
kõripõletik, mis põhjustab hääle kähedust
throat inflammation that causes a hoarse voice;
kõripõletik, mis põhjustab hääle kähedust;
Throat irritation
Kurguärritus
throat irritation
kurguärritus;
Throat irritation
Sinusiit
throat irritation, throat tightness, lip swelling, tongue swelling injection site discolouration, injection site itching and discolouration
kõriärritus, pitsitustunne kõris, huuleturse, keeleturse; värvimuutus süstekohal, värvimuutus ja kihelus süstekohal.
Throat pain
Kurguvalu
throat pain or irritation
kurguvalu või –ärritus
Throat pain, snoring
Kurguvalu, norskamine
throat redness*
neelupunetus
throat tightness
pigistustunne kurgus
Throat tightness
Pitsitustunne kurgus
throat tightness
pitsitustunne kurgus,
Throat tightness Epistaxis
Epistaksis
Throat tightness Epistaxis
Pitsitus kurgus Epistaksis
throat tightness generalized itching
pigistustunne kõris üldine sügelus
Throat tightness Stridor
Pitsitustunne kurgus Striidor
Throat tightness,
Kõripitsitus, ninaturse,
Throat tightness,
Peenise hemorraagia,
Throat tightness, hiccups, throat irritation,
Pitsitustunne kurgus, luksumine, kurguärritus
throat tightness, nose bleeds
pingetunne kõris, nina verejooks
throat tightness, nose bleeds
pitsitus kurgus, ninaverejooksud
throat tightness, nose bleeds;
pingetunne kõris, nina verejooks;
throat tightness, throat irritation, cough
pitsitustunne kurgus, kurguärritus, köha
Thrombin is central to the process of blood clotting.
Trombiin on vere hüübimisel äärmiselt oluline aine.
Thrombin is one of the substances involved in the clotting process, and when it attaches to the PAR-1 receptor it causes the platelets to become ‘sticky’, helping the blood clot to form.
Trombiin on hüübimises osalev aine; seondumisel PAR-1-retseptoriga muudab see trombotsüüdid n-ö kleepuvaks ja aitab nii verel hüübida.
Thrombin plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross- linked framework that stabilises the thrombus.
Trombiin etendab trombide moodustumise protsessis keskset osa, lõhustades fibrinogeeni fibriini monomeerideks ning aktiveerides hüübimisfaktoreid XIII ja XIIIa, mille tulemusel tekib fibriinist kovalentsidemetega seotud võrgustik, mis stabiliseerib trombi.
thrombo-
trombootiline
Thrombo-
trombotsütopeeni
Thrombo- cytopenia
Trombotsüt opeenia
Thrombo- cytopeniaa
Trombotsüto- peeniaa
Thrombocyte count
Trombotsüütide arv
thrombocyte count ≥ 100 x 109/l common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).
trombotsüütide arv ≥ 100 x 109/l üldise toksilisuse kriteeriumi (CTC) mitte-hematoloogiline toksilisus ≤ aste 1 (v.a alopeetsia, iivelduse ja oksendamise jaoks).
thrombocyte count ≥ 100 x 109/l common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).
trombotsüütide arv ≥ 100 x 109/l üldise toksilisuse kriteeriumi (CTC) mittehematoloogiline toksilisus ≤ 1. aste (v.a alopeetsia, iivelduse ja oksendamise jaoks).
Thrombocythaemia Splenomegaly Lymphadenopathy Hypochromasia
trombotsüteemia põrna suurenemine lümfadenopaatia hüpokromaasia
Thrombocythaemia, eosinophilia, international normalised ratio (INR) increased
Trombotsüteemia, eosinofiilia, rahvusvahelise suhtarvu (INR) suurenemine
Thrombocythemia (incl. platelet count increased)A
Trombotsüteemia (k.a trombotsüütide arvu suurenemine)A
thrombocyto
trombotsütopeeni
Thrombocyto- penia
Trombotsüto- peenia
Thrombocytopaenia
Trombotsüto- peenia
thrombocytopaenia
trombotsütopeenia
Thrombocytopaenia**
Trombotsütopeenia
thrombocytopaenia*, e
trombotsütopeenia *, e
Thrombocytopaenia, including acute profound thrombocytopaenia, has been observed with eptifibatide administration post-marketing (see section 4.8)
Turustamisjärgselt on eptifibatiidi manustamisel täheldatud trombotsütopeenia, sh akuutse sügava trombotsütopeenia esinemist (vt lõik 4.8).
Thrombocytopaenia, including acute profound thrombocytopaenia, has been observed with eptifibatide administration post-marketing (see section 4.8).
Turustamisjärgselt on eptifibatiidi manustamisel täheldatud trombotsütopeenia, sh akuutse sügava trombotsütopeenia esinemist (vt lõik 4.8).
Thrombocytopaenia, lymphadenopathy, lymphopenia
Trombotsütopeenia, lümfadenopaatia, lümfopeenia
Thrombocytopaenia, lymphadenopathy, lymphopenia
Trombotsütopeenia, lümfadenopaatia, lümfopeenia.
Thrombocytopaenia, neutropaenia, and anaemia
Trombotsütopeenia, neutropeenia ja aneemia
Thrombocytope nia11
Trombotsütop eenia11
Thrombocytopeni a11
Trombotsütopeeni a11
Thrombocytopeni a; Leukopenia, Pancytopenia
Trombotsütopeenia; leukopeenia, pantsütopeenia
Thrombocytopeni aa
trombotsütopeeniaa
Thrombocytopenia
aneemia trombotsütopeenia
thrombocytopenia
kreatiniinfosfokinaas
Thrombocytopenia
trombo- tsütopeenia
Thrombocytopenia
Trombotsüteemia
Thrombocytopenia
trombotsüto- peenia
Thrombocytopenia
Trombotsütopee nia11
Thrombocytopenia
Trombotsütopeeni a
Thrombocytopenia
Trombotsütopeenia.
Thrombocytopenia
Trombotsütopeenia11
Thrombocytopenia (2)
Trombotsütopeenia (2)
thrombocytopenia (< 100,000 cells/mm3) prothrombin time > 1.2 times control, or International Normalized Ratio (INR) ≥ 2.0 severe hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure > 110 mm Hg on antihypertensive therapy)
trombotsütopeenia (< 100 000 rakku/mm3) protrombiini aeg > 1,2 korra kontrollajast suurem või INR ≥ 2,0 raske hüpertensioon (antihüpertensiivse raviga süstoolne vererõhk > 200 mm Hg või diastoolne vererõhk > 110 mm Hg)
Thrombocytopenia (< 80 x 109/l), anaemia (haemoglobin < 4.5 g/dl)3
Trombotsütopeenia (< 80 x 109/l), aneemia (hemoglobiin < 4,5 g/dl)3
Thrombocytopenia (all grades) occurred in 11.5% of patients treated with Xofigo and 5.6% of patients receiving placebo.
Trombotsütopeeniat (kõik astmed) esines 11,5%-l Xofigo’ga ravitud patsientidest ja 5,6%-l platseebot saanud patsientidest.
Thrombocytopenia (G3/4: 0.6%);
Trombotsütopeenia (3./4. aste: 0,6%);
Thrombocytopenia (G3/4: 0.6%); Febrile neutropenia
trombotsütopeenia (3./4. aste: 0,6%); febriilne neutropeenia
Thrombocytopenia (G3/4: 1.6%);
Neutropeenia (3./4. aste: 59,2%); Trombotsütopeenia (3./4. aste: 1,6%);
Thrombocytopenia (G3/4: 1.6%);
Trombotsütopeenia (3./4. aste: 1,6%);
Thrombocytopenia (G3/4: 1.6%); Febrile neutropenia (G3/4: NA)
Febriilne neutropeenia (G3./4. aste: NA)
Thrombocytopenia (G3/4: 3%)
Trombotsütopeenia (3./4. aste: 3%)
Thrombocytopenia (G3/4: 3%)
Trombotsütopeenia (G3./4. aste: 3%)
Thrombocytopenia (G3/4: 4.0%);
Trombotsütopeenia (3./4. aste: 4,0%);
Thrombocytopenia (G3/4: 5.2%)
Trombotsütopeenia (G3./4. aste: 5,2%)
Thrombocytopenia (G3/4: 8.8%);
Trombotsütopeenia (3./4. aste: 8,8%);
Thrombocytopenia (G3/4: 8.8%); Febrile neutropenia
trombotsütopeenia (3./4. aste: 8,8%); febriilne neutropeenia
Thrombocytopenia (G4: 0.2%)
Trombotsütopeenia (G4. aste: 0,2%)
Thrombocytopenia (in some cases reversible platelet counts less than 5000 mm3).
Trombotsütopeenia (mõnel juhul on taastuvate vereliistakute arv väiksem kui 5000 mm³ kohta).
Thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), granulocytopenia (low levels of granulocytes, a type of white blood cell), conjunctivitis (inflammation of the membrane that lines the eyelid), corneal opacity (clouding of the cornea, the transparent layer in front of the pupil), keratitis (inflammation of the cornea), photophobia (increased sensitivity of the eyes to light) and eye pain are also common (seen in between 1 and 10 patients in 100).
Trombotsütopeenia (vereliistakute vähesus), leukopeenia (vere valgeliblede vähesus), granulotsütopeenia (vere teatud valgeliblede granulotsüütide vähesus), konjunktiviit (silma sidekesta põletik), silma sarvkesta hägusus, keratiit (sarvkestapõletik), fotofoobia (valguskartus) ja silmavalu on samuti sagedad (esinenud 1–10 patsiendil 100st).
thrombocytopenia (low blood platelet counts);
trombotsütopeenia (vereliistakute vähesus);
Thrombocytopenia (low number of blood platelets)
Trombotsütopeenia (vereliistakute vähesus)
Thrombocytopenia (low platelet count)
Trombotsütopeenia (madal vereliistakute arv)
Thrombocytopenia (platelet count decreased)
trombotsütopeenia (trombotsüütide arvu vähenemine)
Thrombocytopenia (some very rare cases were severe with platelet counts less than 5,000 per mm3).
Trombotsütopeenia (mõned väga harvad juhud olid tõsised, kus trombotsüütide arv oli väiksem kui 5000 mm3 kohta).
Thrombocytopenia (some very rare cases were severe with platelet counts less than 5.000 per mm3).
Trombotsütopeenia (mõned väga harvad juhud olid tõsised, kus trombotsüütide arv oli väiksem kui 5000 mm3 kohta).
Thrombocytopenia (very common).
Trombotsütopeenia (väga sage).
Thrombocytopenia *
Trombotsütop eenia
Thrombocytopenia < 25,000/mm3
Trombotsütopeenia < 25 000/mm3
Thrombocytopenia a
Trombotsüto- peeniaa
Thrombocytopenia Anaemia
trombotsüto- peenia, aneemia
Thrombocytopenia Anaemia
Trombotsütopeenia, aneemia
Thrombocytopenia and Immunogencity related to GP IIb/IIIa inhibitors
Trombotsütopeenia ja GP IIb/IIIa inhibiitoritega seotud immunogeensus
Thrombocytopenia and Neutropenia
Trombotsütopeenia ja neutropeenia
thrombocytopenia bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly
trombotsütopeenia, luuhaigus pärast teiste põhjuste, nt D-vitamiini puuduse kõrvaldamist, hepatomegaalia või splenomegaalia.
Thrombocytopenia f
Trombotsütopeenia
Thrombocytopenia Febrile neutropenia Anaemia Pancytopenia Granulocytopenia
Trombotsütopeenia Febriilne neutropeenia Aneemia Pantsütopeenia Granulotsütopeenia
Thrombocytopenia has been reported commonly in patients receiving filgrastim.
Filgrastiimi saavatel patsientidel on sageli teatatud trombotsütopeenia juhtudest.
Thrombocytopenia has been reported commonly in patients receiving filgrastim.
Filgrastiimi saavatel patsientidel on sageli teatatud trombotsütopeeniast.
Thrombocytopenia has been reported very commonly in patients receiving filgrastim.
Filgrastiimi saavatel patsientidel on väga sageli teatatud trombotsütopeenia juhtudest.
Thrombocytopenia has been reported very commonly in patients receiving filgrastim.
Filgrastiimi saavatel patsientidel on väga sageli teatatud trombotsütopeeniast.
Thrombocytopenia in patients with a positive in-vitro aggregation test in the presence of enoxaparin,
trombotsütopeenia patsientidel, kelle in vitro agregatsiooni analüüs on enoksapariini kasutamisel positiivne;
Thrombocytopenia is a known complication of apheresis and has been observed in patients receiving Mozobil.
Trombotsütopeenia on afereesi teadaolev tüsistus ja seda on täheldatud ka Mozobil’i saanud patsientidel.
Thrombocytopenia Leukocytosis
Trombotsüto- peenia
Thrombocytopenia Leukopenias/neutrop enia
trombotsütopeenia leukopeeniad/ neutropeenia
Thrombocytopenia Neutropenia Anaemia Lymphopenia
Trombotsütopeenia Neutropeenia Aneemia Lümfopeenia
Thrombocytopenia occurred in 27.0% of patients who received Pom + LD-Dex, and 26.8% of patients who received HD-Dex.
Trombotsütopeenia tekkis 27,0% patsientidest, kes said Pom + LD-Dex ravi, ja 26,8% patsientidest, kes said HD-Dex ravi.
Thrombocytopenia occurred in 27.0% of relapsed and refractory multiple myeloma patients who received Pom + LD-Dex, and 26.8% of patients who received HD-Dex.
Trombotsütopeenia esines 27,0%-l retsidiveerunud ja refraktoorse hulgimüeloomiga patsientidest, kes said Pom + LD-Dex-i, ning 26,8%-l patsientidest, kes said HD-Dex-i.
Thrombocytopenia or coagulation defects;
trombotsütopeenia või hüübimishäired;
Thrombocytopenia or decreased platelet counts were reported in 24.9% of patients in clinical studies with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (2.6%).
Trombotsütopeeniat ehk trombotsüütide arvu langust kirjeldati 24,9%-l trastuzumabemtansiini kliinilistes uuringutes osalenud patsientidest ning see oli kõige sagedasem ravi lõpetamiseni viinud kõrvaltoime (2,6%).
Thrombocytopenia or functional platelet defects
Trombotsütopeenia või trombotsüütide funktsionaalsed defektid
Thrombocytopenia Splenic rupture
Trombotsüto- peenia Põrnarebend
Thrombocytopenia was Grade 3 or 4 in 20.7% of patients who received Pom + LD-Dex and in 24.2% who received HD-Dex.
III või IV astme trombotsütopeenia esines 20,7%-l patsientidest, kes said Pom + LD-Dex-i, ja 24,2%-l patsientidest, kes said HD-Dex-i.
Thrombocytopenia was observed in 50% of patients, and was severe (< 50,000 cells/mm3) in 9 %.
Trombotsütopeeniat esines 50 %-l patsientidest, rasket vormi (< 50 000 rakku/mm3) esines 9 %-l.
Thrombocytopenia was reported in approximately 40% of subjects in clinical studies with Kyprolis and approximately 20% of subjects had grade ≥ 3 events.
Trombotsütopeeniast teatati ligikaudu 40% uuritavatest Kyprolis’e kliinilistes uuringutes ning ligikaudu 20% uuritavatest olid ≥ 3. raskusastme juhud.
Thrombocytopenia#
Trombotsütopeenia#
Thrombocytopenia*
Trombotsütopeenia
Thrombocytopenia*, coagulopathy*.
trombotsütopeenia*, koagulopaatia
Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia*
Trombotsütopeenia*, palavikuga neutropeenia, neutropeenia*, leukopeenia*, aneemia*, lümfopeenia
Thrombocytopenia*, Neutropenia*, Anaemia*
Trombotsütopeenia*, neutropeenia*, aneemia
Thrombocytopenia,
Trombotsütopeenia
thrombocytopenia,
trombotsütopeenia,
Thrombocytopenia, anaemia and leukopenia
trombo- tsüto- peenia, aneemia ja leuko- peenia
thrombocytopenia, anaemia, leukopenia
Febriilne neutropeenia, trombotsütopeenia, aneemia, leukopeenia
Thrombocytopenia, eosinophilia
Harv: trombotsütopeenia, eosinofiilia
thrombocytopenia, eosinophilia
Trombotsütopeenia, eosinofiilia
thrombocytopenia, increased international normalised ratio (INR)
trombotsütopeenia, rahvusvahelise standardsuhte (INR) väärtuste suurenemine
Thrombocytopenia, leucopenia, eosinophilia
leukopeenia, eosinofiilia
Thrombocytopenia, Leukocytopenia, Neutropenia, Anaemia*
Febriilne neutropeenia, pantsütopeenia
Thrombocytopenia, leukopenia
trombotsütopeenia, leukopeenia
Thrombocytopenia, Leukopenia, Haemolysis*
trombotsütopeenia, leukopeenia, hemolüüs
thrombocytopenia, leukopenia, leukocytosis, haemorrhagic diathesis
trombotsütopeenia, leukopeenia, leukotsütoos,
thrombocytopenia, neutropenia (blood disorders)
trombotsütopeenia, neutropeenia (muutused verepildis)
thrombocytopenia, neutropenia, anaemia, leukopenia
trombotsütopeenia, neutropeenia, aneemia, leukopeenia
thrombocytopenia, neutropenia, leukocytosis, polycythaemia, lymphopenia
trombotsütopeenia, neutropeenia, leukotsütoos, polütsüteemia, lümfopeenia
Thrombocytopenia, neutropenia, leukopenia, lymphopenia
Trombotsütopeenia, neutropeenia, leukopeenia, lümfopeenia
Thrombocytopenia, or decreased platelet counts, was commonly reported with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (see section 4.8).
Trastuzumabemtansiini kasutamisel on sageli kirjeldatud trombotsütopeeniat ehk trombotsüütide arvu langust, mis oli kõige sagedasem ravi lõpetamiseni viinud kõrvaltoime (vt lõik 4.8).
Thrombocytopenia, purpura, leukopenia, anemia, methemoglobinemia, agranulocytosis
Trombotsütopeenia, purpur, leukopeenia, aneemia, methemoglobineemia, agranulotsütoos
Thrombocytopenia, thrombocytopenic purpura
trombotsütopeenia, trombotsütopeeniline purpur
Thrombocytopenia, thrombocytopenic purpura
trombotsütopeenia, trombotsütopeeniline purpura
Thrombocytopenia1
Trombotsütop eenia11
Thrombocytopenia1
Trombotsütopeenia
Thrombocytopenia1 Leukocytosis1
Trombotsütopeenia1 Leukotsütoos1
Thrombocytopenia11
Leukopeenia10 Neutropeenia10
Thrombocytopenia11
Trombotsüto peenia11
Thrombocytopenia11
Trombotsütop eenia11
Thrombocytopenia11
Trombotsütopeen ia11
Thrombocytopenia11
Trombotsütopeeni a11
Thrombocytopenia11
Trombotsütopeenia
Thrombocytopenia11
Trombotsütopeenia1
Thrombocytopenia:
Trombotsütopeenia:
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25 % of patients (15 % of courses).
Trombotsütopeenia: Raske vorm (trombotsüüte alla 25 x 109/l) arenes 25 %-l patsientidest (8 % kuuride lõikes), mõõdukas vorm (trombotsüüte vahemikus 25,0…50,0 x 109/l) 25 %-l patsientidest (15 % kuuride lõikes).
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25% of patients (15 % of courses).
Trombotsütopeenia: Raske vorm (trombotsüüte alla 25 x 109/l) arenes 25 %-l patsientidest (8 % kuuride lõikes), mõõdukas vorm (trombotsüüte vahemikus 25,0…50,0 x 109/l) 25 %-l patsientidest (15 % kuuride lõikes).
Thrombocytopenia; Leukopenia, Pancytopenia
Trombotsütopeenia; leukopeenia, pantsütopeenia
Thrombocytopeniaa
Trombotsüto- peeniaa
Thrombocytopeniaa
trombotsütopeeniaa
Thrombocytopeniaa Leukocytosisa
Splenomegaaliaa Aneemia
Thrombocytopeniaa Leukocytosisa
Trombotsütopeeniaa Leukotsütoosa
Thrombocytopeniab
Trombotsütopeeniab
thrombocytopeniab, lymphopeniab
trombotsütopeeniab, lümfopeeniab
Thrombocytopeniab,c
Trombotsütopeeniab,c
thrombocytopenic
trombotsütopeeniline
Thrombocytosis
Trombotsütoos
Thrombocytosis (see section 4.4)
Trombotsütoos (vt lõik 4.4)
Thromboembo lism (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
Trombemboolia (sh kopsuarteri emboolia ja süvaveenide tromboos) (vt lõik 4.4)
Thromboemboli sm (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
Trombemboolia (sh kopsuarteri emboolia ja süvaveenide tromboos) (vt lõik 4.4)
thromboembolic
trombemboolsed ja isheemilised
Thromboembolic complications may occur if the preparation is unintentionally applied intravascularly (see section 4.4).
Toote tahtmatul intravaskulaarsel kasutamisel võivad tekkida trombemboolsed tüsistused (vt lõik 4.4) Ohutuse kohta nakkustekitajate ülekandumise osas vt lõik 4.4.
Thromboembolic event
Trombembooliline sündmus
thromboembolic events
tromb- emboolsed nähud
Thromboembolic events
Trombembooliajuhud
Thromboembolic events - arterial and venous
Trombembooliad – arteriaalsed ja venoossed
Thromboembolic events are commonly observed in women with advanced breast cancer and have been observed in clinical trials with Faslodex (see section 4.8).
Kliinilistes uuringutes Faslodexiga on kaugelearenenud rinnavähiga naistel sageli täheldatud trombemboolilisi juhte (vt lõik 4.8).
Thromboembolic events ITP patients
Trombemboolsed tüsistused ITP patsiendid
Thromboembolic events Tabulated list of adverse reactions
Kõrvaltoimete tabel
Thromboembolic events, both in association with and separate from OHSS, have been reported following treatment with gonadotropins, including Puregon.
Pärast ravi gonadotropiinidega, sh Puregon’iga, on teatatud trombemboolilistest tüsistustest nii seoses OHSS-iga kui ka sellest eraldi.
Thromboembolic events, including pulmonary embolism
Trombemboolsed tüsistused, sh kopsuarteri trombemboolia
Thromboembolic events: In patients with VWD, there is a risk of occurrence of thromboembolic events, particularly in patients with known clinical or laboratory risk factors.
Trombemboolilised sündmused. vWD-ga patsientidel, eriti teadaolevate kliiniliste või laboratoorsete riskiteguritega patsientidel, esineb trombembooliliste sündmuste tekkerisk.
Thromboembolic reactions such as myocardial infarction (tight band around the chest with feeling like your heart is beating too fast), stroke (muscle weakness in the face, arm, or leg, trouble speaking or understanding others who are speaking), pulmonary embolism (shortness of breath, chest pain and fatigue), deep vein thromboses (pain and swelling in an extremity).
Trombemboolilised reaktsioonid, nagu müokardiinfarkt (pitsitustunne rindkeres ja südametegevuse kiirenemine), insult (näo, käsivarre või sääre lihase nõrkus, kõnehäire või kõnest arusaamise häire), kopsuemboolia (hingeldus, valu rindkeres ja väsimus), süvaveenitromboos (jäseme valu ja turse).
Thromboembolis
Trombembooli
Thromboembolis m (including
Trombemboolia (sh
Thromboembolis m (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
Trombembooli a (sh kopsuarteri emboolia ja süvaveenide tromboos) (vt lõik 4.4)
Thromboembolism
Trombembolism
Thromboembolism
Trombembooli
Thromboembolism (including
Trombemboolia (sh
Thromboembolism (including pulmonary
Trombemboolia (sh kopsuarteri
Thromboembolism (including pulmonary embolism and deep vein thrombosis) (see section 4.4.)
Trombemboolia (sh kopsuemboolia ja süvaveenide
Thromboembolism (increased risk of blood clots)*
trombemboolia (tõusnud risk verehüüvete tekkimiseks)*;
Thromboembolism (problems with blood clots in the blood vessels) may occur very rarely, usually associated with severe OHSS.
Trombemboolia (soonesisesed verehüübed) esineb väga harva ja on tavaliselt seotud munasarja raske hüperstimulatsiooni sündroomiga.
Thromboembolism (pulmonary embolism, deep vein thrombosis)*
Trombemboolia (kopsuemboolia, süvaveeni tromboos)
Thromboembolism may occur very rarely, usually associated with severe OHSS (see section 4.4).
Väga harva võib esineda trombembooliat, tavaliselt on see seotud raske OHSS-ga (vt lõik 4.4).
Thromboembolism, usually associated with severe OHSS (see section 4.4).
Trombemboolia, tavaliselt seoses raske munasarjade hüperstimulatsioonisündroomiga (OHSS) (vt lõik 4.4).
Thromboembolism:
Trombemboolia
ThromboGenics NV Gaston Geenslaan 1 B-3001 Leuven Belgium
ThromboGenics NV Gaston Geenslaan 1 B-3001 Leuven Belgia